PARCLYA
Live / Applied — Fourth extension granted (statement of use) (as of 06 Sept 2025)
What this means for you
Not registered yet, but its 05 Nov 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97662905
- Mark type
- Stylized text
- Filed
- 05 Nov 2022
- Published for opposition
- 18 Jul 2023
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; all of the above excluding contraceptives
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 03 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Sept 2025 — SOU EXTENSION 4 GRANTED
- 06 Sept 2025 — SOU EXTENSION 4 FILED
- 06 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Mar 2025 — SOU EXTENSION 3 GRANTED
- 10 Mar 2025 — SOU EXTENSION 3 FILED
- 10 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 09 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Sept 2024 — SOU EXTENSION 2 GRANTED
- 09 Sept 2024 — SOU EXTENSION 2 FILED
- 09 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 09 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Mar 2024 — SOU EXTENSION 1 GRANTED